Lv31
260 积分 2024-02-04 加入
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
7小时前
待确认
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
26天前
已完结
[Research progress in neoadjuvant therapy for epithelial ovarian cancer]
26天前
已完结
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
1个月前
已完结
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
1个月前
已完结
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
1个月前
已完结
Recent advances in therapeutic cancer vaccines
3个月前
已完结
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
3个月前
已完结
Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study
3个月前
已完结
Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors
3个月前
已完结
皖公网安备34019202002308
